An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living
Key facts
- Who runs it
- Bijan Najafi, PhD
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 64 people enrolled
- Started
- 1 Nov 2021
- Ended
- 31 Dec 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- IADLSys system
- Record updated
- 13 March 2025
- Why it stopped
- The PI has moved to another institution
Who can take part
- Age
- 50 years to 95 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 50 years or older
- Ambulatory and are living independently in a residential home with a caregiver/informant
- Willing and able to provide informed consent
Who cannot take part
- residing in a nursing home or are receiving hospice care
- Patients with any clinically significant medical or psychiatric condition
- Recent stroke over last 6 months
- major hearing/visual impairment
- any acute diagnosis that may impact IADL (e.g., fracture, foot ulcer, recent surgery, etc)
- Under 50 years
- immobility or inability to engage in IADL that are essential for independent living
- inability to communicate in English
- are unlikely to fully comply with the follow-up protocol
Where in United States
- Baylor College of MedicineHouston, United States
About the trial
What the trial wants to find out
Difficulties in performing instrumental activity of daily living (IADL) is often an indicator of cognitive decline in older adults, and monitoring IADL and daily functioning can assist in early diagnosis of dementia. The current methods for assessment of IADL are often restricted to a single domain assessment (e.g. managing medication), or rely on subjective reporting by the patient or caregivers. Patients with mild AD typically lack awareness of their IADL deficits and generally overestimate their functional capacity. Proxies are also not always a reliable source of information, as they have a tendency to over or underestimate IADL deficits. In some cases, a proxy is not available or does not have enough knowledge about the patient's functional capacity. Direct measures taken during performance of IADL-related tasks in the clinic have better validity and do not suffer from reporter bias. However, they allow observation of only a small set of tasks and, even then, are quite time-consuming. To date, there are no objective methods for continuous and remote monitoring and assessment of IADL. The National Institute on Aging (NIA) has identified this need and released a specific request for SBIR/STTR applications. In response, BioSensics, in collaboration with Baylor College of Medicine (BCM), proposes to develop and commercialize a robust system for objective and continuous remote monitoring of IADL. This innovative platform, called IADLSys, will detect the timing and type of IADL for a wide range of daily functions, and will also monitor the user's physical activity and life-space.
The 2 groups in the trial
- Cognitive Impaired Group
older adults (age 50 years and older) with either clinical diagnosis of cognitive impairment or determined to have cognitive impairment based on Montreal Cognitive Assessment (MoCA) Test, score of 26 or lower
Treatment: IADLSys system
- Cognitive Intact Group
Older adults age matched with Cognitive Impaired Group with MoCA score of greater than 26
Treatment: IADLSys system
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 March 2025